H6PD and renal cell carcinoma: Considerable accumulated evidence has demonstrated that G6PDH exhibits higher enzyme activities in RCC patients, which could be used as a biomarker for clinical diagnosis (Spencer and Stanton, 2017; Zhang et al., 2017b).